Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
ABSTRACT: A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The initial results showed that ibrutinib-containing regimens had superior progression-free survival (PFS) and rituximab did not add additional benefits. Here we present an updated analysis. With a median follow-up of 55 months, the median PFS was 44 months (95% confidence interval [CI], 38-54) for BR and not yet reached in either ibrutinib-containing arm. The 48-month PFS estimates were 47%, 76%, and 76% for BR, ibrutinib, and IR, respectively. The benefit of ibrutinib regimens over chemoimmunotherapy was consistent across subgroups of patients defined by TP53 abnormalities, del(11q), complex karyotype, and immunoglobulin heavy chain variable region (IGHV). No significant interaction effects were observed between the treatment arm and del(11q), the complex karyotype, or IGHV. However, a greater difference in PFS was observed among the patients with TP53 abnormalities. There was no difference in the overall survival. Notable adverse events with ibrutinib included atrial fibrillation (afib) and hypertension. Afib was observed in 11 patients (pts) on BR (3%) and 67 pts on ibrutinib (18%). All-grade hypertension was observed in 95 pts on BR (27%) and 263 pts on ibrutinib (55%). These data show that ibrutinib regimens prolong PFS compared with BR for older patients with treatment-naïve CLL. These benefits were observed across subgroups, including high-risk groups. Strikingly, within the ibrutinib arms, there was no inferior PFS for patients with abnormalities in TP53, the highest risk feature observed in CLL. These data continue to demonstrate the efficacy of ibrutinib in treatment-naïve CLL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Blood - 143(2024), 16 vom: 18. Apr., Seite 1616-1627 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Woyach, Jennifer A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1X70OSD4VX |
|---|
| Anmerkungen: |
Date Completed 19.04.2024 Date Revised 19.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2023021959 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367059444 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367059444 | ||
| 003 | DE-627 | ||
| 005 | 20240419232225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2023021959 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM367059444 | ||
| 035 | |a (NLM)38215395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Woyach, Jennifer A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2024 | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ABSTRACT: A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The initial results showed that ibrutinib-containing regimens had superior progression-free survival (PFS) and rituximab did not add additional benefits. Here we present an updated analysis. With a median follow-up of 55 months, the median PFS was 44 months (95% confidence interval [CI], 38-54) for BR and not yet reached in either ibrutinib-containing arm. The 48-month PFS estimates were 47%, 76%, and 76% for BR, ibrutinib, and IR, respectively. The benefit of ibrutinib regimens over chemoimmunotherapy was consistent across subgroups of patients defined by TP53 abnormalities, del(11q), complex karyotype, and immunoglobulin heavy chain variable region (IGHV). No significant interaction effects were observed between the treatment arm and del(11q), the complex karyotype, or IGHV. However, a greater difference in PFS was observed among the patients with TP53 abnormalities. There was no difference in the overall survival. Notable adverse events with ibrutinib included atrial fibrillation (afib) and hypertension. Afib was observed in 11 patients (pts) on BR (3%) and 67 pts on ibrutinib (18%). All-grade hypertension was observed in 95 pts on BR (27%) and 263 pts on ibrutinib (55%). These data show that ibrutinib regimens prolong PFS compared with BR for older patients with treatment-naïve CLL. These benefits were observed across subgroups, including high-risk groups. Strikingly, within the ibrutinib arms, there was no inferior PFS for patients with abnormalities in TP53, the highest risk feature observed in CLL. These data continue to demonstrate the efficacy of ibrutinib in treatment-naïve CLL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a ibrutinib |2 NLM | |
| 650 | 7 | |a 1X70OSD4VX |2 NLM | |
| 650 | 7 | |a Bendamustine Hydrochloride |2 NLM | |
| 650 | 7 | |a 981Y8SX18M |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 700 | 1 | |a Perez Burbano, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Ruppert, Amy S |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Cecelia |e verfasserin |4 aut | |
| 700 | 1 | |a Heerema, Nyla A |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Weiqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wall, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Bartlett, Nancy L |e verfasserin |4 aut | |
| 700 | 1 | |a Brander, Danielle M |e verfasserin |4 aut | |
| 700 | 1 | |a Barr, Paul M |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Kerry A |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Sameer A |e verfasserin |4 aut | |
| 700 | 1 | |a Stephens, Deborah M |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Jennifer R |e verfasserin |4 aut | |
| 700 | 1 | |a Lozanski, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Blachly, James |e verfasserin |4 aut | |
| 700 | 1 | |a Nattam, Sreenivasa |e verfasserin |4 aut | |
| 700 | 1 | |a Larson, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Erba, Harry |e verfasserin |4 aut | |
| 700 | 1 | |a Litzow, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Luger, Selina |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Kuzma, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Abramson, Jeremy S |e verfasserin |4 aut | |
| 700 | 1 | |a Little, Richard F |e verfasserin |4 aut | |
| 700 | 1 | |a Dinner, Shira |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Richard M |e verfasserin |4 aut | |
| 700 | 1 | |a Uy, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Stock, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Mandrekar, Sumithra J |e verfasserin |4 aut | |
| 700 | 1 | |a Byrd, John C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 143(2024), 16 vom: 18. Apr., Seite 1616-1627 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2024 |g number:16 |g day:18 |g month:04 |g pages:1616-1627 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2023021959 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2024 |e 16 |b 18 |c 04 |h 1616-1627 | ||